CONRAD, Eastern Virginia Medical School, Arlington, Virginia; FHI 360, Durham, North Carolina; the California Family Health Council, Los Angeles, California; the University of Pittsburgh, Pittsburgh, Pennsylvania; Johns Hopkins Community Physicians, Baltimore, Maryland; the University of Pennsylvania, Philadelphia, Pennsylvania; Baylor College of Medicine, Houston, Texas; and PATH, Seattle, Washington. Dr. Creinin is currently affiliated with the University of California, Davis, Sacramento, California.
Corresponding author: Jill L. Schwartz, MD, CONRAD, 1911 Fort Myer Drive, Suite 900, Arlington, VA 22209; e-mail: [email protected].
† Deceased.
Supported by CONRAD through USAID funding. Gynol II was provided by Johnson & Johnson. BufferGel was provided by Thomas Moench of ReProtect.
Presented at the International Conference on Family Planning: Research and Best Practices, November 15–18, 2009, Kampala, Uganda, and at Reproductive Health 2011, September 15–17, 2011, Las Vegas, Nevada.
The authors thank Chalyce Grace and Belinda Irsula for study monitoring and the Eunice Kennedy Shriver National Institute of Child Health and Human Development for providing the data for the historical control analysis.
The opinions expressed herein do not necessarily reflect the opinions of U.S. Agency for International Development.
Financial Disclosure Dr. Schwartz, Ms. Callahan, and Dr. Mauck are employees of CONRAD, an organization that contributed to the development of the single-size diaphragm, but will not receive any royalties for commercial sales. Ms. Kilbourne-Brook is an employee of PATH. PATH has a limited royalty interest in commercial sales of the single-size contraceptive barrier device (SILCS) diaphragm to support advocacy for adoption of the SILCS diaphragm in low-resource settings. The other authors did not report any potential conflicts of interest.
